The Application dimension of COVID-19 Rapid Test segmentation distinguishes four primary end‑use groups: clinical laboratory, point‑of‑care (POC), home testing, and surveillance/screening. Clinical laboratories, typically located in hospitals and reference centers, command the largest share (approximately 40%) because they process high‑volume specimens, require stringent quality controls, and integrate results into electronic health records, thereby driving revenue through bulk procurement. POC settings—such as urgent care clinics, pharmacies, and mobile testing units—represent about 35% of the market; their growth is anchored in rapid turnaround times, decentralized access, and reimbursement incentives for immediate decision‑making. Home testing, accounting for roughly 15%, leverages consumer‑direct sales channels and regulatory allowances for over‑the‑counter kits, expanding market size through volume sales despite lower per‑unit price. Surveillance and mass‑screening programs, often run by governments or large employers, contribute the remaining 10%, reflecting episodic demand spikes during outbreaks and the need for inexpensive, high‑throughput testing solutions. Together, these application segments define the overall market structure and guide manufacturers' product‑allocation strategies.